|Bid||3.0600 x 3100|
|Ask||3.0700 x 1300|
|Day's Range||2.9400 - 3.1600|
|52 Week Range||1.4300 - 27.3300|
|Beta (3Y Monthly)||2.53|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
GM Sues Fiat Chrysler Over Corrupt Union Dealings General Motors (NYSE:GM) is suing Fiat Chrysler (NYSE:FCAU) alleging racketeering regarding its negotiations with the United Auto Workers union from back in 2015. Fiat Chrysler executives have already pleaded guilty in an ongoing probe into the UAW, whose own executives accepted bribes from Chrysler people over the […]The post Market Morning: GM Sues Fiat, Pharma Fights for Pricing Privacy, More Opioid Lawsuits, Trade Deal Troubles appeared first on Market Exclusive.
Miller Value Partners recently released its 2019 Q3 investor letter – you can download a copy here. We just published another article about Bill Miller's comments earlier today. The investment management firm did not have a good third quarter, experiencing a 1.81% decline, while the S&P 500 rose 1.70%. One of the top contributors for the fund over the […]
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan ...
Moody's Investors Service commented on Mallinckrodt International Finance SA's ("Mallinckrodt") announced offer to exchange existing unsecured notes for new second-lien secured notes that carry a longer dated maturity. If completed, the offer will help Mallinckrodt address its April 2020 $698 million debt maturity and extend the maturities of its other unsecured notes. If there is full participation from bondholders, Mallinckrodt will also reduce total debt by around $810 million of aggregate principal, or 14% of today's debt.
Mallinckrodt Plc said on Tuesday it has received a subpoena from the U.S. Securities and Exchange Commission for documents related to the drugmaker's lawsuit against the U.S. Department of Health and Human Services (HHS). The lawsuit against the HHS and the Centers for Medicare and Medicaid Services was filed in May over changes in the calculation of Medicaid discounts for Acthar gel, the company's biggest money-spinner. Changes to the Medicaid rebate calculations could result in a near 10% hit to annual sales of Acthar, its costly treatment for multiple sclerosis and a rare infant seizure disorder, the company said in May.
Shares of the generic drugmaker sank after the company reported better-than-expected earnings but a sales miss. It raised its guidance for the full year.
Mallinckrodt (MNK) delivered earnings and revenue surprises of 4.55% and -3.71%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Shares of Mallinckrodt PLC fell 1.3% in premarket trading Tuesday, after the drug maker reported a third-quarter adjusted profit that beat expectations, but sales that fell short, as branded and generic drug sames missed. The company swung to a net loss of $1.1 million, or 1 cent a share, from net income of $113.8 million, or $1.37 a share, in the year-ago period. Excluding non-recurring items, adjusted earnings per share came to $2.07, above the FactSet consensus of $1.96. Sales declined 7.0% to $743.7 million, below the FactSet consensus of $770.5 million, as specialty branded drug sales fell 9.3% to $580.4 million to miss expectations of $596.5 million and specialty generic sales rose 2.1% to $163.3 million but missed expectations of $169.5 million. The company raised its 2019 adjusted EPS guidance range to $8.50 to $8.70 from $8.40 to $8.70. "We remain focused on strengthening our balance sheet through debt reduction and we also are working to resolve near term uncertainties in our business, particularly opioid litigation and the separation of our Specialty Generics segment," said Chief Executive Mark Trudeau. The stock has tumbled 40.6% over the past three months while the S&P 500 has climbed 8.2%.
On Tuesday, November 5, Mallinckrodt (NYSE: MNK ) will report its last quarter's earnings. Here is Benzinga's preview of the company's release. Earnings and Revenue Mallinckrodt earnings will be near $1.98 per ...
Investors are looking forward to the performance of Specialty Brands and other pipeline updates, when Mallinckrodt (MNK) reports Q3 results.
Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients' money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth also depends on it. Regardless of the various methods used by elite investors like David Tepper and David […]
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Oct. 31) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ...
Investors will look forward to regular top and bottom-line numbers, when Mylan (MYL) reports Q3 results along with updates on merger with Upjohn.
Mallinckrodt (MNK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Two charities will pay $6 million to resolve claims they operated as pass-throughs for seven pharmaceutical companies to pay kickbacks to Medicare patients using their high-priced medications, the U.S. Justice Department said on Friday. The settlements with the patient assistance charities Good Days and Patient Access Network Foundation were the first with foundations linked to an industry-wide probe that has resulted in $840 million in settlements with drugmakers. Good Days agreed to pay $2 million while PAN Foundation agreed to pay $4 million.
Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
J&J (JNJ) voluntarily recalls one lot of its baby powders, which is the subject of numerous lawsuits claiming that its talc-based products contain asbestos that causes cancer.
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
Shares of companies embroiled in the U.S. opioid crisis were trading sharply higher Wednesday following a Tuesday Wall Street Journal report that said three opioid drug distributors are in talks with ...